Advanced NanoTherapies Reports Positive Human Trial Results for Dual-Drug Coated Balloon, Plans U.S. Feasibility Study

First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase Novel Nanoparticle Technology Platform Aims to Deliver Two Proven Drugs for Vessel Patency and Restenosis Prevention SANTA CLARA, Calif., Oct. 26, 2024 — Advanced NanoTherapies (ANT), a clinical-stage medical device company focused on innovative nanotechnology solutions for…

Explore Nanchang’s Culinary Scene

NANCHANG, China, Oct. 26, 2024 — A report from Jiangxi International Communication Center(JXICC): “Is it city or not?” Recently, the 144-Hour Visa-Free Transit has not only sparked a craze for “China Travel” but also this catchphrase. Many Chinese cities have rolled out 144-hour visa-free transit for international travelers. Tips for Nanchang…

RiboX Therapeutics’ Circular RNA Therapy for Radiation-Induced Dry Mouth Gets FDA Approval for Clinical Trial

PRINCETON, N.J., Oct. 25, 2024 — RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company specializing in the discovery and development of fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration (FDA) has cleared its IND application for the Phase I/IIa Study of RXRG001 (SPRINX-1 Study) on October…